Central Nervous System
This session updates participants on emerging trends in central nervous system radiation oncology, with special attention to high grade and low grade gliomas and brain metastases. Additionally, various benign tumors are reviewed. Focus is on trends in the last five years, as well as the types of therapies and techniques that we could be seeing in the next few years as clinical trials develop and report.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe recent advancements in the treatment of high grade glioma and low grade glioma with radiotherapy.
- Describe recent advancements in the treatment of brain metastases with radiotherapy.
Planning Committee Disclosures
The person(s) above served as the developer(s) of this activity. Additionally, ASTRO Education Committee had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.